PDCD1 and neoplasm: All of these observations imply that immunotherapy should be considered as a potential treatment for those patients exhibiting increased expression of PD-1 and/or PD-L1 in tumor and/or increased numbers of cytolytic effector memory T cells in peripheral blood.